MacroGen signs 17.98 billion KRW genome and transcriptome data supply contract with Korea Research Institute of Biosciences
MacroGen has signed a contract with the Korea Research Institute of Biosciences to produce genome and transcriptome data for the national bio‑big‑data project. The contract value equals 13.54% of its latest revenue.
AI comment — why bullish
The newly signed contract could add a material amount to MacroGen's top line, given that its value represents 13.54% of the company's most recent revenue. If the revenue from this project is recognized in the upcoming reporting period, earnings may see a comparable uplift. The counterparty, Korea Research Institute of Biosciences, is a domestic public research entity, which may reduce collection risk. Because the contract is tied to a national big‑data initiative, execution is likely to proceed under stable governmental oversight. However, the filing does not disclose the timing of revenue recognition, so the exact impact on the next quarter remains uncertain. Overall, the deal points to a near‑term positive contribution to MacroGen's financial performance.
Market data
마크로젠 · 038290 · KOSDAQ →Previous-close data, updated T+1 · Source: Financial Services Commission of Korea via data.go.kr
Key takeaway
"MacroGen signs 17.98 billion KRW genome and transcriptome data supply contract with Korea Research Institute of Biosciences" — BullBear's AI rates this story as a bullish (positive) signal for markets, with a market-impact score of 58 out of 100. That score reflects how strongly the story is likely to move Bitcoin, US equities, the dollar, and gold, and near-duplicate coverage of the same event is clustered so only the representative article is scored. Reported by 금융감독원 전자공시(DART) on September 10, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 46.0%.